Drug name - Belbuca
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(10 years from now) | |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: FILM;BUCCAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.075MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.15MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.3MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.45MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.6MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.75MG BASE | FILM;BUCCAL | Prescription |
| EQ 0.9MG BASE | FILM;BUCCAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.